Piramal Pharma Limited (PPLPHARMA.NS)
INR 219.87
(-1.68%)
INR 219.87
(-1.68%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 81.71 Billion INR | 15.39% |
| 2022 | 70.81 Billion INR | 128.78% |
| 2021 | 30.95 Billion INR | 5.33% |
| 2020 | 29.38 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 22.41 Billion INR | 14.89% |
| 2024 Q1 | 19.51 Billion INR | -23.56% |
| 2023 Q1 | 17.48 Billion INR | -19.17% |
| 2023 FY | 81.71 Billion INR | 15.39% |
| 2023 Q4 | 25.52 Billion INR | 30.32% |
| 2023 Q3 | 19.58 Billion INR | 2.47% |
| 2023 Q2 | 19.11 Billion INR | 9.29% |
| 2022 Q1 | 14.81 Billion INR | 211.23% |
| 2022 FY | 70.81 Billion INR | 128.78% |
| 2022 Q4 | 21.63 Billion INR | 26.08% |
| 2022 Q3 | 17.15 Billion INR | -0.23% |
| 2022 Q2 | 17.2 Billion INR | 16.06% |
| 2021 Q1 | 14.62 Billion INR | 0.0% |
| 2021 FY | 30.95 Billion INR | 5.33% |
| 2021 Q4 | -13.32 Billion INR | -186.57% |
| 2021 Q3 | 15.39 Billion INR | -2.43% |
| 2021 Q2 | 15.77 Billion INR | 7.84% |
| 2020 FY | 29.38 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Biocon Limited | 147.55 Billion INR | 44.624% |
| Blue Jet Healthcare Limited | 7.11 Billion INR | -1048.283% |
| Concord Biotech Limited | 9.98 Billion INR | -718.707% |
| Dishman Carbogen Amcis Limited | 26.15 Billion INR | -212.381% |
| Jubilant Ingrevia Limited | 41 Billion INR | -99.275% |
| Lyka Labs Limited | 1.05 Billion INR | -7672.264% |
| Panacea Biotec Limited | 5.59 Billion INR | -1361.302% |
| SMS Lifesciences India Limited | 3.05 Billion INR | -2570.677% |
| Supriya Lifescience Limited | 5.7 Billion INR | -1332.607% |
| Syngene International Limited | 34.88 Billion INR | -134.225% |
| TAKE Solutions Limited | 656.08 Million INR | -12354.518% |
| Zota Health Care Limited | 1.8 Billion INR | -4427.247% |